CBD Products Face New Regulatory Pathway as Market Booms (2)

The Food and Drug Administration intends to collaborate with Congress to devise a harm reduction approach to potential regulatory pathways for cannabidiol products, an agency official said Wednesday.

The FDA believes a new pathway for cannabidiol products is needed to protect consumer safety given CBD’s inherent risk profile and the limited risk management options that exist underthe current food ingredient and dietary supplement pathways, Norman Birenbaum, a senior public health adviser for the FDA’s Center for Drug Evaluation and Research, said at a Food and Drug Law Institute conference.

“A new pathway could implement much-needed standards over the largely unregulated ...